ECTRIMS 2021 | Delaying MS treatment to boost COVID-19 vaccination effects

Anat Achiron, MD, PhD, Sheba Medical Center and Tel-Aviv University, Tel Aviv, Israel, discusses the debate of if and when disease modifying treatment should be stopped in patients with multiple sclerosis (MS), particularly highlighting important considerations in the COVID-19 era. It remains unclear whether DMTs should be used indefinitely and what factors should be considered when thinking about discontinuation. Prof. Achiron comments on the potential benefits of temporarily discontinuing treatment to maximize the likelihood of mounting a successful immune response to COVID-19 vaccination. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress 2021.